ReviewAdvanced materials (Deerfield Beach, Fla.)2025
Advances and Strategies in Enhancing mRNA Cancer Vaccines.
Review in Advanced materials (Deerfield Beach, Fla.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Critical chemistry manufacturing and controls considerations for mRNA lipid nanoparticle translation.Discover nano · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Silk-Based Protein Corona Enhances mRNA-LNP Vaccine Efficacy and Prevents Tumor Relapse.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Immune protection in chickens via lipid nanoparticle-encapsulated VP2 DNA vaccine against very virulent infectious bursal disease virus.Poultry science · 2026Article
- A lipid nanoparticle-based mRNA vaccine elicits immunity against porcine circovirus type 2 in mice.Microbiology spectrum · 2026Article
- A symphony of immunity: How HPV mRNA-LNP vaccination orchestrates systemic anti-tumor responses.Molecular therapy. Nucleic acids · 2026Article
- Review
- Extracellular vesicles delivering TIMP-2 modulate MMP-1, MMP-2, and MMP-9 expression in human lung adenocarcinoma A549 cells.Frontiers in pharmacology · 2026Article
- Advances and Strategies in Enhancing mRNA Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Messenger RNA (mRNA) vaccine has emerged as a promising strategy in cancer immunotherapy, enabling the induction of precise and robust immune responses against tumor antigens. Nevertheless, enormous challenges remain, in particular its limitations in achieving optimal immunogenicity and therapeutic efficacy, result in modest clinical benefit. Here, the biological barriers are reviewed that impede the functionality of mRNA cancer vaccine and describe the design considerations, including structure engineering, chemical modification, and development of next-generation delivery materials for enhancing cancer immunotherapy. Recent advances are highlighted aimed at improving vaccine efficacy through targeted delivery, modulation of immune cell interactions, and stimulation of innate immune responses. Finally, the challenges are examined in clinical translation and explore future directions for improving the therapeutic potential of mRNA cancer vaccines. By synthesizing current progress and identifying critical hurdles, this review provides a framework for advancing mRNA-based cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.